Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 29

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 29
---
358,750,000,000
Ordinary Shares under this prospectus. As of January 15, 2025, there were 6,685,918,922 Ordinary Shares outstanding. If all of the 358,750,000,000
Ordinary Shares offered for resale by the Selling Shareholder under this prospectus were issued and outstanding as of January 15, 2025,
such shares would represent approximately 98.2% of total number of Ordinary Shares outstanding.

The actual number of Depositary
Shares issuable will vary depending on the then current market price of our Depositary Shares sold to the Selling Shareholder in this
offering and the number of Depositary Shares we ultimately elect to sell to the Selling Shareholder under the Purchase Agreement. If it
becomes necessary for us to issue and sell to the Selling Shareholder under the Purchase Agreement more than the 350,000,000,000 Ordinary
Shares being registered for resale under this prospectus in order to receive aggregate gross proceeds equal to $35.0 million under
the Purchase Agreement, we must file with the SEC one or more additional registration statements to register under the Securities Act
the resale by the Selling Shareholder of any such additional Depositary Shares we wish to sell from time to time under the Purchase Agreement,
which the SEC must declare effective, in each case before we may elect to sell any additional Depositary Shares under the Purchase Agreement.

In addition, the Selling Shareholder
is not obligated to buy any Depositary Shares under the Purchase Agreement if such shares, when aggregated with all other securities then
beneficially owned by the Selling Shareholder and its affiliates (as calculated pursuant to Section 13(d) of the Exchange Act, and Rule
13d-3 promulgated thereunder), would result in the Selling Shareholder beneficially owning Ordinary Shares in excess of the Beneficial
Ownership Limitation. Our inability to access a portion or the full amount available under the Purchase Agreement, in the absence of any
other financing sources, could have a material adverse effect on our business or results of operation.

| 15 |

The Selling Shareholder will pay less than the then-prevailing market price for our Depositary Shares, which could cause the price of our Depositary Shares to decline.

The purchase price of our
Depositary Shares to be sold to the Selling Shareholder under the Purchase Agreement is derived from the market price of our Depositary
Shares on the NASDAQ. Shares to be sold to the Selling Shareholder